相关实验视频

Updated: Jan 8, 2026

Routine Screening Method for Microparticles in Platelet Transfusions

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

血小板抗体查以预防输血后的血小板折射性:系统性审查和元分析

Yanling Zhuang¹, Mingquan Wang¹

¹Department of Blood Transfusion, Quanzhou First Hospital Affiliated to Fujian Medical University, No. 248-252, East Street, Licheng District, Quanzhou 362000 Fujian Province, China.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine

|December 19, 2025

概括

血小板抗体查通过识别有风险的患者,显著降低了输血后的血小板折射率 (PTR). 这改善了结果,特别是对于那些需要与HLA匹配的血小板的人来说.

科学领域:

输血医学输血医学
免疫学免疫学免疫学

背景情况:

输血后的血小板折射性 (PTR) 是一个显著的并发症,特别是由人类白细胞抗原 (HLA) 与免疫接种引起的免疫媒介的PTR.
这种并发症导致无效的血小板输血和血液恶性瘤患者或接受血造干细胞移植 (allo-HSCT) 的患者的不良结果.

研究的目的:

评估血小板抗体查的有效性,特别是使用平均光强度 (MFI) 值检测抗HLA抗体.
评估查对降低免疫介导PTR和改善输血结果的影响.

主要方法:

按照PRISMA指南进行系统审查和元分析.
搜索了主要的数据库 (PubMed,Embase,Cochrane,Scopus,Web of Science) 进行了搜索.
分析结果包括PTR发病率,生存率和并发症,计算相对风险 (RRs) 和赔率 (ORs) 与基于MFI值的子组分析.

主要成果:

包括7项涉及2865名患者的研究.
抗体查将PTR发生率降低了46% (15.4%与28.6%相比).
高的MFI门 (>10,000) 增加了特异性,而较低的门 (>5000) 增加了PTR预测的敏感性. 接受兼容输血的查患者的死亡率和并发症降低.

结论:

血小板抗体查有效地识别出患有免疫媒介PTR风险的患者.
针对性输血协议 (例如,与HLA匹配的血小板) 可以改善高风险人群的临床结果.
标准化MFI门和协议对于临床实施至关重要;进一步的前性研究是合理的.

关键词:

允许免疫接种.人类白细胞抗原 (HLA)平均光强度 (MFI) 是指血小板输血并发症血小板输血并发症输血后的血小板折射率 (PTR)干细胞移植干细胞移植

更多相关视频

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Published on: August 24, 2015

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro

Published on: March 19, 2016

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Blood Transfusion

Blood Transfusion

Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...

Blood Transfusion and Agglutination

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...